<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250535</url>
  </required_header>
  <id_info>
    <org_study_id>10-0576</org_study_id>
    <secondary_id>1R01GM089994-01A1</secondary_id>
    <nct_id>NCT01250535</nct_id>
  </id_info>
  <brief_title>Human Cytochrome P450 4F Enzymes and Drug Interactions</brief_title>
  <official_title>Human Cytochrome P450 4F Enzymes and Drug Interactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-drug interactions play an important role in clinical adverse events due to the
      prevalence of multi-drug therapy. Co-administration of warfarin and a statin has expanded
      substantially in the US over the last decades. The purpose of this study is to develop a
      mechanistic understanding of the role of a drug-metabolizing enzyme, CYP4F2, in the
      interaction between warfarin and statins. This study will test the hypothesis that lovastatin
      potentiates the anticoagulant effect of warfarin by inducing vitamin K-metabolizing enzyme
      CYP4F2 in humans, thus increasing warfarin's anticoagulant effect.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Measurement will be performed before (baseline) and 2, 4, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144, and 168h after co-administration of warfarin and lovastatin/placebo and during screening.</time_frame>
    <description>Measurement of Prothrombin time (PT) to assess the International Normalized Ratio (INR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Sampling will be performed before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, and 168 h after co-administration of warfarin and lovastatin/placebo.</time_frame>
    <description>Vitamin K1 and vitamin K1 metabolite measured by maximum plasma concentration and AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Sampling will be performed before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60, 72, 96, 120, 144, and 168 h after co-administration of warfarin and lovastatin/placebo.</time_frame>
    <description>Pharmacokinetics for (R)- and (S)- Warfarin, and lovastatin measured by maximum plasma concentration and AUC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Drug Drug Interactions</condition>
  <arm_group>
    <arm_group_label>Warfarin plus lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin plus lovastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Warfarin plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>10 mg, po, single dose on day 7</description>
    <arm_group_label>Warfarin plus lovastatin</arm_group_label>
    <arm_group_label>Warfarin plus placebo</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>po, once a day, days 1 through 14</description>
    <arm_group_label>Warfarin plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin</intervention_name>
    <description>40 mg, po, once a day, days 1 through 14</description>
    <arm_group_label>Warfarin plus lovastatin</arm_group_label>
    <other_name>Mevacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal baseline clinical laboratory results including coagulation panel (prothrombin
             time (PT), international normalized ratio (INR), activated partial thromboplastin time
             (APTT)), liver function tests (ALT, AST, alkaline phosphatase and total bilirubin),
             kidney function tests (serum creatinine and BUN), lipid panel (cholesterol, LDL-C,
             HDL-C, and triglycerides), and blood creatine kinase

          -  Minimum weight of 110 lbs and minimum hemoglobin level at 12.5 g/dL

          -  Ability to understand the informed consent form

          -  Willing to abstain from grapefruit products, alcohol, and physical contact sports

        Exclusion Criteria:

          -  History of intolerance, allergy, or hypersensitivity to study drugs warfarin and
             lovastatin or any substances contained in the medication

          -  History of clotting disorders, stroke, hypertension, anemia, renal insufficiency,
             hepatic dysfunction, platelet dysfunction, gastrointestinal bleeding, or any recent
             bleeding episode or trauma within 6 months

          -  History of significant medical conditions that the study physician believes would
             increase risk (e.g., additional bleeding disorders)

          -  Genotype non-homozygous for CYP2C9*1 or genotype VKORC1-1639AA

          -  History of significant alcohol abuse and/or illicit drug use

          -  Tobacco use within the month preceding the study

          -  Woman who is pregnant or breastfeeding

          -  Women who are unable to maintain adequate birth control during the study

          -  Post-menopausal women on estrogen replacement

          -  Chronic statin or warfarin use

          -  Taking concomitant medications, both prescription and non-prescription (including
             herbal products, over-the-counter medications, and multivitamins), known to alter
             lovastatin, warfarin, or vitamin K blood levels (women stabilized on hormonal methods
             of birth control will be allowed to participate, and subjects stabilized on
             antidepressant medications will be allowed to participate)

          -  Recent use of antibacterial antibiotics

          -  Recent blood donation or participation in other clinical studies within past 8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Z Wang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim LR Brouwer, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina, Clinical and Translational Research Center (CTRC)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Kim Brouwer, PharmD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug drug interactions</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Anticoagulants</keyword>
  <keyword>Lovastatin</keyword>
  <keyword>Statins</keyword>
  <keyword>CYP4F2</keyword>
  <keyword>Vitamin K</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

